Skip to main content

Advertisement

SpringerLink
Log in

SKIN CANCER

Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Clinical trials of neoadjuvant therapy for melanoma have expanded rapidly over the past several years. Preliminary data demonstrate the prognostic value of pathological response, which might have clinical implications for refining the roles of surgery and adjuvant therapy. These clinical questions are under active investigation across many ongoing clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Leiter, U. et al. Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J. Clin. Oncol. 37, 3000–3008 (2019).

    Article  CAS  Google Scholar 

  2. Faries, M. B. et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 376, 2211–2222 (2017).

    Article  Google Scholar 

  3. Reijers, I. L. M. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat. Med. 28, 1178–1188 (2022).

    Article  CAS  Google Scholar 

  4. Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).

    Article  CAS  Google Scholar 

  5. Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 27, 256–263 (2021).

    Article  CAS  Google Scholar 

  6. Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301–309 (2021).

    Article  CAS  Google Scholar 

  7. Long, G. V. et al. Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Cancer Res. 81 (Suppl.), CT004 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Giorgos C. Karakousis & Tara C. Mitchell

  2. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Giorgos C. Karakousis

  3. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Tara C. Mitchell

Authors
  1. Giorgos C. Karakousis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tara C. Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tara C. Mitchell.

Ethics declarations

Competing interests

G.C.K. has participated on scientific advisory boards for Merck. T.C.M. has participated on scientific advisory boards for Bristol Myer Squibb, GigaGen, Instil Bio, Merck and OncoSec.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karakousis, G.C., Mitchell, T.C. Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma. Nat Rev Clin Oncol 19, 679–680 (2022). https://doi.org/10.1038/s41571-022-00677-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00677-3

  • Springer Nature Limited

Search

Navigation